PSMA-Avid Metastatic Prostate Cancer With Intense Penile Uptake on PET/CT: A Rare Site of Spread.

Clin Nucl MedAug 24, 2026 (epub)
Case ReportUrologyRadiology (Diagnostic)Pathology (Anatomic & Clinical)

Katarzyna Klappa, Witold Cholewinski, Mikolaj Kuta et al.

✦ AI-curated · Sources linked

Case in brief

A 64-year-old man with biopsy-proven advanced prostatic adenocarcinoma (cT3bN1M1, Gleason 4+4=8) had intense, diffuse, homogeneous PSMA uptake throughout the corpora cavernosa along the penile shaft on PET/CT (SUVmax=76.9). Histopathology of sampled penile tissue confirmed metastatic prostatic adenocarcinoma (Grade Group 3, Gleason 4+3=7), involving 100% of the sample. The report describes penile involvement by metastatic disease; it does not state a clinical outcome or how the metastasis resolved.

What made this case unusual

The penile metastasis appeared as diffuse, homogeneous uptake along the corpora cavernosa rather than as focal deposits, with histology confirming extensive involvement of the sampled tissue.

Diagnostic / clinical pearl

Assess the external genitalia on PSMA PET/CT in advanced prostate cancer: penile metastasis may present as diffuse, intense uptake, and histopathology can confirm its prostatic origin.

Source

PubMed · PMID 42640591

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Urology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.